查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1604580

抗精神病药物市场：按类别、适应症 - 2025-2030 年全球预测

Antipsychotic Drugs Market by Class (First Generation, Second Generation, Third Generation), Indication (Bipolar Disorders, Dementia, Schizophrenia) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗精神病药物市场价值为96.5亿美元，预计到2024年将达到104.2亿美元，复合年增长率为8.01%，到2030年将达到165.6亿美元。

抗精神病药物市场主要包括用于治疗思觉失调症和双相情感障碍等精神病相关疾病的药物。这个市场的范围延伸到各种心理健康应用，包括严重忧郁症和焦虑症的治疗。精神疾病发病率的上升以及全球意识和诊断率的提高支持了对这些药物的需求。主要的最终用途领域包括医院、诊所和復健中心，它们利用这些药物来稳定患者的心理状态并提高他们的生活品质。该市场的关键成长要素包括精神健康疾病盛行率的增加、药物配方的进步以及心理健康支持措施。开发副作用较少、疗效较强的下一代抗精神病药物的机会比比皆是。投资精神疾病的遗传和生物学基础的研究可以带来个人化的药物治疗策略，并为公司的创新提供利润丰厚的机会。数位疗法与药物治疗相结合也代表了一个潜在的成长领域，特别是当科技融入医疗保健服务时。然而，影响市场开拓的限制因素包括药物开发成本高、监管要求严格以及与精神疾病相关的耻辱感，这些可能会阻碍市场扩张。与现有抗精神病药物相关的副作用（例如体重增加和代谢问题）等挑战可能会阻止患者坚持制定的治疗方案。为了克服这些限制，製药公司可能会专注于透过新型药物传输系统（例如缓释性和经皮贴片）来减少副作用。总的来说，个人化医疗的创新、利用人工智慧进行药物发现以及综合心理健康服务的整合有潜力推动业务的显着增长并改变治疗格局，抗精神病药物突显了这一持续、复杂但充满希望的性质的药品市场。

主要市场统计
基准年[2023] 96.5亿美元
预测年份 [2024] 104.2亿美元
预测年份 [2030] 165.6亿美元
复合年增长率（%） 8.01%

市场动态：揭示快速发展的抗精神病药物市场的关键市场洞察

供需的动态交互作用正在改变抗精神病药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 精神疾病和相关疾病的盛行率增加
    • 政府药品审批增加
    • 人们对心理健康和保健的认识不断增强
  • 市场限制因素
    • 现有品牌专利到期
  • 市场机会
    • 新型抗精神病药物的研发及临床试验
    • 改良抗精神病药物测试
  • 市场问题
    • 严格的法律规范和合规性

波特的五力：驾驭抗精神病药物市场的策略工具

波特五力：「框架是了解市场格局竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解抗精神病药物市场的外部影响

外部宏观环境因素在塑造抗精神病药物市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解抗精神病药物市场的竞争格局

抗精神病药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：抗精神病药物市场供应商的绩效评估

FPNV定位矩阵是评估抗精神病药物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製抗精神病药物市场的成功之路

抗精神病药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 精神疾病和相关疾病的盛行率增加
      • 政府药品核准增加
      • 人们对心理健康和保健的认识不断增强
    • 抑制因素
      • 现有品牌专利到期
    • 机会
      • 新型抗精神病药物的研发及临床试验
      • 改良抗精神病药物测试
    • 任务
      • 严格的法规结构和合规性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章抗精神病药物市场：依类别

  • 介绍
  • 第一代
    • 哈尔德
    • 纳瓦内
  • 第二代
    • 象齿象
    • 因维加
    • 拉图达
    • Risperdal
    • Seroquel
    • Zyprexa
  • 第三代
    • Abilify

第七章抗精神病药物市场：依适应症分类

  • 介绍
  • 躁郁症
  • 失智
  • 思觉失调症
  • 单相忧郁症

第八章美洲抗精神病药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太抗精神病药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的抗精神病药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alkermes, Inc.
  • AMBOSS GmbH
  • Amgen Inc
  • Arlak BIoTech
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories, Ltd.
  • Eli Lilly and Company
  • Flagship BIoTech International Pvt. Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services Inc.
  • Lifecare Neuro Products Ltd.
  • Luye Pharma Group
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co. Ltd.
  • Pfizer, Inc.
  • S. Karger AG
  • Seqirus Pty Ltd
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries, Ltd.
  • Vanda Pharmaceuticals Inc.
Product Code: MRR-AD36CD897CDF

The Antipsychotic Drugs Market was valued at USD 9.65 billion in 2023, expected to reach USD 10.42 billion in 2024, and is projected to grow at a CAGR of 8.01%, to USD 16.56 billion by 2030.

The antipsychotic drugs market encompasses medications primarily used to manage psychosis-related conditions such as schizophrenia and bipolar disorder. This market's scope extends to diverse mental health applications, including the treatment of severe depression and anxiety disorders. The necessity for these drugs is underscored by the rising incidence of mental health disorders and the expansion of awareness and diagnosis rates worldwide. The primary end-use sectors include hospitals, clinics, and rehabilitation centers, which utilize these medications to stabilize patients' psychological states and enhance their quality of life. Key growth factors for this market include the increasing prevalence of mental health conditions, advancements in drug formulations, and supportive mental health policies. Opportunities abound in developing next-generation antipsychotic drugs with fewer side effects and enhanced efficacy profiles. Investments in research focused on the genetic and biological underpinnings of psychiatric disorders could lead to personalized medication strategies, presenting a lucrative opportunity for businesses to innovate. Digital therapeutics, combined with pharmacological treatments, also represent a potential area for growth, especially as technology integrates into healthcare delivery. However, limitations affecting market growth include the high cost of drug development, stringent regulatory requirements, and the stigma associated with mental health disorders, which may hinder market expansion. Challenges such as side effects associated with existing antipsychotic drugs, including weight gain and metabolic issues, can deter patients from adherence to prescribed treatment regimes. To overcome these limitations, pharmaceutical companies might focus on reducing adverse effects through novel drug delivery systems, such as sustained-release formulations or transdermal patches. Overall, innovation in personalized medicine, leveraging artificial intelligence for drug discovery, and integrating comprehensive mental health services could drive significant business growth and transform the treatment landscape, highlighting the ongoing complex yet promising nature of the antipsychotic drugs market.

KEY MARKET STATISTICS
Base Year [2023] USD 9.65 billion
Estimated Year [2024] USD 10.42 billion
Forecast Year [2030] USD 16.56 billion
CAGR (%) 8.01%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antipsychotic Drugs Market

The Antipsychotic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of psychosis and associated diseases
    • Rising drug approval from governments
    • Growing awareness regarding mental health and wellness
  • Market Restraints
    • Patent expiry of established brands
  • Market Opportunities
    • R&D and clinical trials for new antipsychotic drugs
    • Improvements in antipsychotic drug testing
  • Market Challenges
    • Stringent regulatory framework and compliance

Porter's Five Forces: A Strategic Tool for Navigating the Antipsychotic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antipsychotic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antipsychotic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antipsychotic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antipsychotic Drugs Market

A detailed market share analysis in the Antipsychotic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antipsychotic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antipsychotic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antipsychotic Drugs Market

A strategic analysis of the Antipsychotic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antipsychotic Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes, Inc., AMBOSS GmbH, Amgen Inc, Arlak Biotech, AstraZeneca PLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Company, Flagship Biotech International Pvt. Ltd., GlaxoSmithKline PLC, H. Lundbeck A/S, Johnson & Johnson Services Inc., Lifecare Neuro Products Ltd., Luye Pharma Group, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co. Ltd., Pfizer, Inc., S. Karger AG, Seqirus Pty Ltd, Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries, Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Antipsychotic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Class, market is studied across First Generation, Second Generation, and Third Generation. The First Generation is further studied across Haldo and Navane. The Second Generation is further studied across Geodon, Invega, Latuda, Risperdal, Seroquel, and Zyprexa. The Third Generation is further studied across Abilify.
  • Based on Indication, market is studied across Bipolar Disorders, Dementia, Schizophrenia, and Unipolar Depression.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of psychosis and associated diseases
      • 5.1.1.2. Rising drug approval from governments
      • 5.1.1.3. Growing awareness regarding mental health and wellness
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of established brands
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D and clinical trials for new antipsychotic drugs
      • 5.1.3.2. Improvements in antipsychotic drug testing
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework and compliance
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antipsychotic Drugs Market, by Class

  • 6.1. Introduction
  • 6.2. First Generation
    • 6.2.1. Haldo
    • 6.2.2. Navane
  • 6.3. Second Generation
    • 6.3.1. Geodon
    • 6.3.2. Invega
    • 6.3.3. Latuda
    • 6.3.4. Risperdal
    • 6.3.5. Seroquel
    • 6.3.6. Zyprexa
  • 6.4. Third Generation
    • 6.4.1. Abilify

7. Antipsychotic Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Bipolar Disorders
  • 7.3. Dementia
  • 7.4. Schizophrenia
  • 7.5. Unipolar Depression

8. Americas Antipsychotic Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antipsychotic Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Antipsychotic Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkermes, Inc.
  • 3. AMBOSS GmbH
  • 4. Amgen Inc
  • 5. Arlak Biotech
  • 6. AstraZeneca PLC
  • 7. Bristol-Myers Squibb Company
  • 8. Daiichi Sankyo Company, Limited
  • 9. Dr. Reddy's Laboratories, Ltd.
  • 10. Eli Lilly and Company
  • 11. Flagship Biotech International Pvt. Ltd.
  • 12. GlaxoSmithKline PLC
  • 13. H. Lundbeck A/S
  • 14. Johnson & Johnson Services Inc.
  • 15. Lifecare Neuro Products Ltd.
  • 16. Luye Pharma Group
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co. Ltd.
  • 20. Pfizer, Inc.
  • 21. S. Karger AG
  • 22. Seqirus Pty Ltd
  • 23. Sumitomo Dainippon Pharma Co., Ltd.
  • 24. Teva Pharmaceutical Industries, Ltd.
  • 25. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. ANTIPSYCHOTIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIPSYCHOTIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIPSYCHOTIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALDO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY NAVANE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GEODON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INVEGA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LATUDA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERDAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SEROQUEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ZYPREXA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ABILIFY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY UNIPOLAR DEPRESSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIRD GENERATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023